This acceptable use policy sets out the terms between you and us under which you may access our website diabetes.ascensia.ie (our site). This acceptable use policy applies to all users of, and visitors to, our site.
Your use of our site means that you accept, and agree to abide by, all the policies in this acceptable use policy, which supplement our terms of website use.
diabetes.ascensia.ie is a site operated by Ascensia Diabetes Care Ireland Limited (we or us). We are registered in Ireland under company number 569145 and we have our registered office at 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland.
Medical questions
The comments facility is not intended as a forum to gain medical advice. If you have a question about your diabetes monitoring or management, you should contact your diabetes healthcare professional. Any queries relating to blood glucose meters should be directed to Ascensia Diabetes Support on 1 800 920111 (freephone) or by email diabetesssupport@ascensia.com
Ascensia Diabetes Care and your comments
Comments will be pre-moderated by Ascensia Diabetes Care for content standards compliance each working day. Any enquiries about Ascensia Diabetes Care products should be directed to Ascensia Diabetes Support on diabetesssupport@ascensia.com or call 1 800 920111 (freephone) (IE).
The Product Review facilities are provided for your use. The views and opinions that are expressed by users may not reflect those of Ascensia Diabetes Care.
Prohibited uses
You may use our site only for lawful purposes. You may not use our site:
You also agree:
The use of any of our interactive services by a minor is subject to the consent of their parent or guardian. We advise parents who permit their children to use an interactive service that it is important that they communicate with their children about their safety online, as moderation is not foolproof. Minors who are using any interactive service should be made aware of the potential risks to them.
Content standards
These content standards apply to any and all material which you contribute to our site (contributions), and to any interactive services associated with it.
You must comply with the spirit of the following standards as well as the letter. The standards apply to each part of any contribution as well as to its whole.
Contributions must:
Contributions must not:
Suspension and termination
We will determine, in our discretion, whether there has been a breach of this acceptable use policy through your use of our site. When a breach of this policy has occurred, we may take such action as we deem appropriate. Failure to comply with this acceptable use policy constitutes a material breach of the terms of use upon which you are permitted to use our site, and may result in our taking all or any of the following actions:
We exclude liability for actions taken in response to breaches of this acceptable use policy. The responses described in this policy are not limited, and we may take any other action we reasonably deem appropriate.
Changes to the acceptable use policy
We may revise this acceptable use policy at any time by amending this page. You are expected to check this page from time to time to take notice of any changes we make, as they are legally binding on you. Some of the provisions contained in this acceptable use policy may also be superseded by provisions or notices published elsewhere on our site.
* IQVIA data January 2023
§ Minimum accuracy requirements of ISO15197: 2013 Section 6.3 standard require ≥95% of the measured values to fall within ±0.83 mmol/L at glucose concentrations <5.5 mmol/L or within ±15% at glucose concentrations ≥5.5 mmol/L compared to the reference method.
† An ad hoc analysis demonstrated that 95% of the results were within the error range ±0.3 mmol/L or ±5.3% of the laboratory reference values (Hexokinase (HK)-based method (Cobas Integra 400 Plus; Roche Instrument Center, Rotkreuz, Switzerland).
** Patients need to be registered in GlucoContro.online and approve sharing their data with their healthcare professional. For a list of compatible devices, please visit compatibility.contourone.com
SdNcenter is the legal manufacturer and developer of GlucoContro.online and is partnering with Ascensia to market and deliver the tool to HCP and Patient users
1. Pleus S et.al, User Performance Evaluation and System Accuracy Assessment of Four Blood Glucose Monitoring Systems With Color Coding of Measurement Results. J Diabetes Sci Technol. 2022 Nov 26:19322968221141926. doi: 10.1177/19322968221141926.
2. International Organization for Standardization. In vitro diagnostic test systems — requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus (ISO 15197). International Organization for Standardization, Geneva, Switzerland, 2013.
3. CONTOUR®NEXT BGMS User Guide, Rev. 12/21.